These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32391356)

  • 1. A Dual TLR7/TLR9 Inhibitor HJ901 Inhibits ABC-DLBCL Expressing the MyD88 L265P Mutation.
    An B; Zhu S; Li T; Wu J; Zang G; Lv X; Qiao Y; Huang J; Shao Y; Cui J; Liu YJ; Chen J
    Front Cell Dev Biol; 2020; 8():262. PubMed ID: 32391356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenically active MYD88 mutations in human lymphoma.
    Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
    Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.
    Boudesco C; Verhoeyen E; Martin L; Chassagne-Clement C; Salmi L; Mhaidly R; Pangault C; Fest T; Ramla S; Jardin F; Wolz OO; Weber ANR; Garrido C; Jego G
    Blood; 2018 Aug; 132(5):510-520. PubMed ID: 29871863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma.
    Elbaz O; Shaat RM; Abd El Ghaffar HA; Shamaa S; Abdel-Masseih HM; Anber N; Mortada MI
    Asian Pac J Cancer Prev; 2023 Jul; 24(7):2485-2491. PubMed ID: 37505783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
    Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
    Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
    [No Abstract]   [Full Text] [Related]  

  • 6. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
    Choi JW; Kim Y; Lee JH; Kim YS
    Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.
    Mondello P; Brea EJ; De Stanchina E; Toska E; Chang AY; Fennell M; Seshan V; Garippa R; Scheinberg DA; Baselga J; Wendel HG; Younes A
    JCI Insight; 2017 Mar; 2(6):e90196. PubMed ID: 28352655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling.
    Turi M; Anilkumar Sithara A; Hofmanová L; Žihala D; Radhakrishnan D; Vdovin A; Knápková S; Ševčíková T; Chyra Z; Jelínek T; Šimíček M; Gullà A; Anderson KC; Hájek R; Hrdinka M
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825.
    Wang X; Tan Y; Huang Z; Huang N; Gao M; Zhou F; Hu J; Feng W
    Oncol Rep; 2019 Nov; 42(5):1755-1766. PubMed ID: 31432184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
    Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T
    Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.
    Knittel G; Liedgens P; Korovkina D; Seeger JM; Al-Baldawi Y; Al-Maarri M; Fritz C; Vlantis K; Bezhanova S; Scheel AH; Wolz OO; Reimann M; Möller P; López C; Schlesner M; Lohneis P; Weber AN; Trümper L; ; Staudt LM; Ortmann M; Pasparakis M; Siebert R; Schmitt CA; Klatt AR; Wunderlich FT; Schäfer SC; Persigehl T; Montesinos-Rongen M; Odenthal M; Büttner R; Frenzel LP; Kashkar H; Reinhardt HC
    Blood; 2016 Jun; 127(22):2732-41. PubMed ID: 27048211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting TLR9 and other UNC93B1-dependent TLRs paradoxically increases accumulation of MYD88L265P plasmablasts in vivo.
    Wang JQ; Beutler B; Goodnow CC; Horikawa K
    Blood; 2016 Sep; 128(12):1604-8. PubMed ID: 27458005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
    Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
    J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P.
    Nagakita K; Takata K; Taniguchi K; Miyata-Takata T; Sato Y; Tari A; Ohnishi N; Noujima-Harada M; Omote S; Nakamura N; Iwamuro M; Maeda Y; Okada H; Tanimoto M; Yoshino T
    Pathol Int; 2016 Aug; 66(8):444-52. PubMed ID: 27439595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.
    Xie J; Shen X; Shi Q; Yi H; Ouyang B; Zhang Z; Gu Y; Dong L
    Hematol Oncol; 2022 Dec; 40(5):885-893. PubMed ID: 36053490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
    Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S
    Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.
    Lee JH; Jeong H; Choi JW; Oh H; Kim YS
    Sci Rep; 2017 May; 7(1):1785. PubMed ID: 28496180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Characteristics of PD-L1 expression in tumor cells and tumor microenvironment of DLBCL with MYD88 L265P mutation].
    Fu YL; Xue XM; Shen GH; Yuan LJ; Zheng B; Zhang HF; Qiu T; Huang WT
    Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):751-755. PubMed ID: 34405609
    [No Abstract]   [Full Text] [Related]  

  • 19. DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation.
    Xue X; Huang W; Qiu T; Guo L; Ying J; Lv N
    BMC Cancer; 2020 Aug; 20(1):816. PubMed ID: 32854650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-
    Yoon SB; Hong H; Lim HJ; Choi JH; Choi YP; Seo SW; Lee HW; Chae CH; Park WK; Kim HY; Jeong D; De TQ; Myung CS; Cho H
    Acta Pharm Sin B; 2023 Mar; 13(3):1093-1109. PubMed ID: 36970199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.